Navigation Links
Transposagen Issued Two Key U.S. Patents
Date:11/1/2013

LEXINGTON, Ky., Nov. 1, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today the issuing of Patent No. 8,399,643 entitled, "Nucleic Acids Encoding Hyperactive PiggyBac Transposases" on March 19th and Patent No. 8,558,055 entitled, "A Genetically Modified Rat Comprising a Cytokine Gene Disruption and Exhibiting a Greater Susceptibility to a Cytokine-Mediated Autoimmune and/or Inflammatory Disease" on October 15th. The patents have terms extending through 2030.

(Photo: http://photos.prnewswire.com/prnh/20131101/MN08740)

The piggyBacTM DNA transposon is the most efficient and safe technology for delivering DNA stably into the genome of animals and is being used in biomedical, agricultural and human therapeutic applications. Transposagen tested over 2 million variations of the piggyBacTM transposase enzyme and discovered versions of the enzyme that are more than 10 times more active than the version found in nature. The piggyBacTM technology is also a critical component of Footprint-FreeTM Gene Editing, one of the only commercially available methods to edit as little as a single nucleotide in the genome of nearly any organism. "The new 'super piggyBacTM vectors and PB-GoldTM kit, will allow researchers to perform stable transfection for the same cost and on the same timeline as transient transfection." said Jack Crawford, M.Sc., Transposagen's Director of Sales and Marketing.

The more recent patent covers all genetically modified rats that model lymphocyte proliferation, autoimmune disease or inflammatory disease, including all genetically modified rats with dysfunction in macrophages, immunoglobulin, T-cells, B-cells and/or NK-cells. The patent further covers any assay that screens for potentially useful therapeutic compounds using cells derived from the genetically modified rats. "This patent, and other imminent patents that cover genetically modified rat models of cancer and other diseases, cements Transposagen's position as a premier provider of custom genetically modified rodents," said Eric Ostertag, M.D., Ph.D., President & CEO of Transposagen. "We are proud to be the sole provider of valuable research reagents, such as the hyperactive piggyBacTM transposase and rat models of inflammatory disease, to the research community."

Please see piggyBacTM for more information, as well as Disease Model Partnering Strategy for opportunities in rodent model creation.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen specializes in gene editing tools and custom cell line and animal model creation. To learn more, please visit: http://transposagenbio.com/

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115, jcrawford@transposagenbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Transposagen Biopharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Transposagen Receives Over $4.3M in Grants and Investment
2. Enbrel® (etanercept) Patent Issued
3. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
4. 12th U.S. Patent Issued To Dyadic International
5. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
6. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
7. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
8. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
9. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
10. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... YORK , May 26, 2016 ... investors see value in this space. Today,s pre-market research on ... equities: Radius Health Inc. (NASDAQ: RDUS ), Cerus ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... stock technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder Scientific ... positive developments that position the Company for the future. Kinder Scientific announces ... F. Kinghorn has been appointed Chairman of the Board, Curtis D. Kinghorn has ...
(Date:5/25/2016)... Diego, Calif. (PRWEB) , ... May 25, 2016 , ... ... Diego area and has consistently been rated one of its top attractions. Fortune ... the globe to participate in a unique and intimate team-building experience. , Each event ...
(Date:5/25/2016)... Oregon (PRWEB) , ... May 25, 2016 , ... ... Set features a variety of fracture-specific plating options designed to address fractures of ... industry-leading fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):